Clinical Scorecard: The Role of Radiotherapy in Advanced Bladder Cancer with Metastasis
At a Glance
Category
Detail
Condition
Metastatic bladder cancer (MetBC) with local and distant metastases
Key Mechanisms
Radiotherapy induces cancer cell death via high-energy ionising radiation; stereotactic ablative radiotherapy (SABR) allows precise high-dose treatment of metastases
Target Population
Patients with metastatic bladder cancer including those with symptomatic primary tumors and oligometastatic disease
Care Setting
Oncology and palliative care settings, including outpatient radiotherapy units
Key Highlights
Metastatic bladder cancer has poor prognosis with <10% five-year survival and significant morbidity from urinary symptoms.
Radiotherapy is effective for palliation of urinary symptoms (haematuria, pain, dysuria) with hypofractionated schedules providing symptom relief in majority of patients.
SABR shows promise for targeting oligometastatic lesions to potentially prolong disease control and survival.
Guideline-Based Recommendations
Diagnosis
Identify metastatic bladder cancer by presence of lymph node involvement beyond pelvis or visceral metastases.
Assess performance status and renal function to guide systemic therapy eligibility.
Management
First-line treatment: platinum-based chemotherapy (cisplatin + gemcitabine) for patients with adequate renal function and performance status.
Carboplatin-based chemotherapy for patients with impaired renal function or poor performance status.
Maintenance immunotherapy with avelumab after response or stabilization with chemotherapy.
Palliative radiotherapy for symptom control of primary tumor and metastases, typically 1–5 fractions.
Consider SABR for oligometastatic disease to improve disease control.
Monitoring & Follow-up
Monitor symptom relief and toxicity during and after radiotherapy.
Evaluate renal function and performance status regularly to adjust systemic therapy.
Assess disease progression to identify oligometastatic status and suitability for metastasis-directed radiotherapy.
Risks
Acute grade 3 urinary toxicity in up to 18% and gastrointestinal toxicity in up to 4% during radiotherapy.
Potential for treatment discontinuation or death within one month of starting palliative radiotherapy in patients with poor prognosis.
Need for careful patient selection to balance palliative benefit and treatment burden.
Patient & Prescribing Data
Patients with metastatic bladder cancer including those with symptomatic primary tumors and oligometastatic disease
Hypofractionated radiotherapy schedules (e.g., 36 Gy in 6 weekly fractions) provide durable symptom relief and local control; lower fraction regimens (1–3 fractions) suitable for patients with limited life expectancy; SABR emerging for oligometastatic lesions.
Clinical Best Practices
Select patients for palliative radiotherapy based on performance status, disease burden, symptom severity, and prognosis.
Use hypofractionated radiotherapy schedules with biologically effective dose ≥36 Gy for better haematuria control.
Employ SABR cautiously for oligometastatic disease to potentially improve survival outcomes.
Monitor and manage acute toxicities during radiotherapy to maintain quality of life.
Integrate systemic chemotherapy and maintenance immunotherapy with radiotherapy for comprehensive care.
In precision oncology, theranostics stands out as a transformative approach that tailors cancer treatment to the unique molecular profile of each patient. By integrating advanced diagnostic imaging with targeted therapy, theranostics ensures that treatments are customized to the unique characteristics of each patient's cancer, thereby optimizing efficacy and minimizing adverse effects.
